Related Experiment Video

Updated: Aug 9, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Selectivity and potency of cyclin-dependent kinase inhibitors

Jayalakshmi Sridhar1, Nagaraju Akula, Nagarajan Pattabiraman

  • 1Laboratory for In-silico Biology and Drug Discovery, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.

The AAPS Journal
|April 6, 2006
PubMed

Insights

Cyclin-dependent kinases (CDKs) regulate cell processes and are implicated in diseases. Understanding CDK structures and inhibitor binding is crucial for developing targeted therapies with fewer side effects.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Drug Discovery

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of cellular processes, with 11 known members.
  • CDKs form complexes with cyclins and play specific roles in cell signaling and transcription.
  • Aberrant CDK expression is linked to various diseases, highlighting their therapeutic potential.

Purpose of the Study:

  • To review the structural aspects of CDK isozymes.
  • To analyze the binding modes of known CDK inhibitors.
  • To guide drug discovery and design for targeted CDK inhibition.

Main Methods:

  • Comparative analysis of amino acid residues in CDK isozymes.
  • Examination of structural data for CDK2, CDK5, and CDK6 complexes with inhibitors.
  • Identification of key residues for enhancing inhibitor potency and specificity.

Main Results:

  • Detailed comparison of cyclin binding, substrate binding, and ATP binding sites across CDK isozymes.
  • Insights into the structural basis for inhibitor interactions with CDKs.
  • Identification of specific amino acids at the ATP binding site influencing potency and subtype specificity.

Conclusions:

  • Structural understanding of CDKs and their inhibitors is vital for drug development.
  • Targeting specific CDK isozymes offers a promising therapeutic strategy.
  • The review provides a foundation for designing more effective and selective CDK inhibitors.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...